Mastering the Clinical Development of Personalized Cancer Medicines


A string of innovative clinical trials designed to accelerate the pace at which personalized cancer medicines are developed have been announced, and in some cases initiated, over the past few …

Read More

First FDA-approved Treatment for Rare Form of Non-Hodgkin Lymphoma

FDA approved image

Last week, the U.S. Food and Drug Administration (FDA) announced the first-ever approval of a treatment for Waldenström macroglobulinemia, ibrutinib (Imbruvica).
Waldenström macroglobulinemia, which is also known as lymphoplasmacytic lymphoma, is …

Read More